Form 8-K

8-K — Altimmune, Inc.

Accession: 0001104659-26-118991

Filed: 2026-10-27

Period: 2026-10-23

CIK: 0001326190

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — tm2628339d1_8k.htm (Primary)

EX-99.1 — EXHIBIT 99.1 (tm2628339d1_ex99-1.htm)

GRAPHIC (tm2628339d1_ex99-1img001.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: tm2628339d1_8k.htm · Sequence: 1

false

0001326190

2026-10-23

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

October 23, 2026

ALTIMMUNE, Inc.

(Exact name of registrant as specified in its

charter)

Delaware

001-32587

20-2726770

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

910 Clopper Road, Suite 201S

Gaithersburg, Maryland

20878

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number including

area code: (240) 654-1450

(Former name or former address, if changed since

last report)

Check the appropriate box below if the Form 8-K filing is intended

to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common stock, par value $0.0001 per share

ALT

The NASDAQ Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant

has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant

to Section 13(a) of the Exchange Act. ¨

Item 5.02 Election

of Directors; Appointment of Certain Officers; Departure of Directors or Certain Officers; Compensatory Arrangements of Certain

Officers

On October 23, 2026,

the Board of Directors, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Peter Greenleaf

and Alex Howarth as directors of the Board effective November 2, 2026, and approved an increase in its size from nine to eleven directors.

Mr. Greenleaf (54), most

recently served as the Chief Executive Officer and member of the board of directors of Aurinia Pharmaceuticals Inc. (Nasdaq: AUPH). From

March 2018 to April 2019, Mr. Greenleaf served as the CEO of Cerecor Pharmaceuticals, Inc. (now Avalo Therapeutics, Inc.).

Prior to joining Cerecor, Mr. Greenleaf served as CEO and Chairman of Sucampo Pharmaceuticals, Inc. from March 2014 to

February 2018. From June 2013 to March 2014, he served as CEO and a member of the board of directors of Histogenics Corporation,

a regenerative medicine company. From 2006 to 2013, Mr. Greenleaf was employed by MedImmune LLC, the global biologics arm of AstraZeneca,

where he most recently served as President. From January 2010 to June 2013, he also served as President of MedImmune Ventures.

Mr. Greenleaf also held senior commercial roles at Centocor, Inc. (now Janssen Biotechnology, Johnson & Johnson) from

1998 to 2006 and at Boehringer Mannheim (now Roche Holdings) from 1996 to 1998. Mr. Greenleaf currently serves as Chairman of the

board of directors of Pelthos Therapeutics, Inc. (NYSE: PTHS) and as a member of the board of directors at Revolo Biotherapeutics.

He has also served as a board member of BDSI from 2018 through March 2022 and Antares Pharmaceuticals from 2018 through the second

quarter of 2022 and of Aurinia Therapeutics from 2019 through April 2026. Mr. Greenleaf earned an MBA from St. Joseph’s

University and a B.S. from Western Connecticut State University.

Mr. Howarth (58), most

recently served as the Chief Financial Officer of Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a role he held from May 2021

through May 2024. Prior to joining Madrigal, Mr. Howarth was the Chief Operating Officer of Akcea Therapeutics, Inc. (Nasdaq:

AKCA) from November of 2019 through the acquisition (in October of 2020) by Ionis Pharmaceuticals, Inc. until December 2020.

Before Akcea, Mr. Howarth was the President (from January to November of 2019) and Chief Financial Officer (from September of

2015 to November of 2019) at Lycera Corp. Mr. Howarth has also held roles as Chief Financial Officer and Chief Business Officer

at moksha8 Pharmaceuticals, Inc., from May 2007 to September of 2015, and prior to this served as Chief Business Officer

at Vitae Pharmaceuticals, Inc. and Head of Venture Partnerships at GlaxoSmithKline plc. Mr. Howarth earned a Bachelor of Applied

Science in Biochemistry from the University of Bath and qualified as a Chartered Accountant in the United Kingdom.

Mr. Greenleaf and Mr. Howarth

will be compensated for their service as non-employee directors pursuant to the Company’s Non-Employee Director Compensation Policy.

Each of Mr. Greenleaf and Mr. Howarth will receive an initial equity award of stock options to purchase 160,000 shares of the

Company’s common stock pursuant to the Company’s 2017 Omnibus Incentive Plan. Each of them is also entitled to receive an

annual cash retainer of $40,000 as a member of the Board. The Company also entered into indemnification agreements with Mr. Greenleaf

and Mr. Howarth in substantially the same form as those entered into with the other directors of the Company.

There are no arrangements

or understandings between any of Mr. Greenleaf or Mr. Howarth and any other person pursuant to which any of Mr. Greenleaf

or Mr. Howarth was selected as a director of the Company. Neither of Mr. Greenleaf nor Mr. Howarth has any family relationship

with any director or executive officer of the Company or any direct or indirect material interest in any transaction required to be disclosed

pursuant to Item 404(a) of Regulation S-K.

Resignation and Appointment

of Certain Directors and Officers. On October 23, 2026, each of John Gill, Mitchell Sayare and Dr. Klaus Schafer notified

the Board of Directors (the “Board”) of Altimmune, Inc. (the “Company”), of his decision to retire and not

stand for re-election to the Board at the Company’s 2027 annual meeting of stockholders (the “2027 Annual Meeting”).

Each of Mr. Gill, Mr. Sayare and Dr. Schafer will continue to serve as a director of the Company until the 2027 Annual

Meeting. The foregoing is not due to any disagreement with the Company on any matter relating to the Company’s operations, policies

or practices.

Item 7.01 Regulation FD Disclosure

On October 27, 2026, the Company issued a

press release announcing the appointments to the Board as discussed above. The full text of this press release is attached hereto as Exhibit 99.1

and is incorporated by reference herein. The information in this Item 7.01 and Exhibit 99.1 attached hereto is intended to be furnished

and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange

Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under

the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference to such filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

No.

Description

99.1

Press Release of Altimmune, Inc. dated October 27, 2026

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934,

the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ALTIMMUNE, INC.

By:

/s/ Gregory Weaver

Name: Gregory Weaver

Title: Chief Financial Officer

Dated: October 27, 2026

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: tm2628339d1_ex99-1.htm · Sequence: 2

Exhibit 99.1

Altimmune Appoints Peter Greenleaf and Alex

Howarth, Two Leading Biotech Executives, to Board of Directors to Support Its Strategic Evolution

Board appointments align with successful transition

to late-stage clinical Company developing pemvidutide as a differentiated liver franchise with multiple potential indications

As part of this transition, John M. Gill, Mitchel

Sayare, Ph.D., and Klaus O. Schafer, M.D., MPH, will retire from the Board at the Company’s 2027 Annual Meeting

MORRISTOWN, N.J., October 27, 2026 (GLOBE NEWSWIRE) –

Altimmune, Inc. (Nasdaq: ALT), a biopharmaceutical company advancing pemvidutide, an investigational glucagon/GLP-1 dual

receptor agonist, in serious liver diseases, today announced that Peter Greenleaf and Alex Howarth will join the company’s board

of directors, effective November 2, 2026.

“We are thrilled to welcome Peter and Alex to the Altimmune Board

of Directors,” said Jerry Durso, Chief Executive Officer (CEO) and Chairman of the Board of Altimmune. “These two proven executive

industry leaders bring strategic perspectives in drug development, commercialization and corporate development that will be a valuable

addition to the Altimmune Board as we continue to progress pemvidutide as a differentiated liver franchise. With our Phase 3 MASH trial

funded and ongoing, along with outstanding Phase 2 data in AUD, now is the right time to evolve our Board of Directors.”

As part of a planned transition process, John M. Gill, Mitchel Sayare,

Ph.D., and Klaus O. Schafer, M.D., MPH, will retire from the Board and not stand for reelection at the end of their current one-year terms

at the Company’s 2027 Annual Meeting.

“On behalf of the Board of Directors, I would like to thank

John, Mitch and Klaus for their long-term contributions to Altimmune, culminating with the significant progress that we believe will enable

a successful future addressing serious liver diseases,” said Durso. “Important milestones achieved for the Company include

accelerating the clinical development of pemvidutide, rebuilding the management team with late-stage development capabilities, and securing

needed financing. This Board succession plan is intended to build on our momentum.”

Mr. Greenleaf has extensive experience guiding publicly traded

biopharmaceutical companies through corporate strategy, business development, M&A, advancing drug pipelines, commercialization, and

board governance. He has served on multiple public and private boards during his career and is currently the Chairman of Pelthos Therapeutics

(Nasdaq: PTHS) and a director of Revolo Biotherapeutics, a private biotechnology company. Mr. Greenleaf most recently served as CEO

at Aurinia Pharmaceuticals, where he scaled the company from a single-asset development-stage company to a commercial enterprise. Previously,

he was CEO and Chairman of Sucampo Pharmaceuticals, overseeing its sale for approximately $1.2 billion, and has also served as CEO of

Cerecor and Histogenics. Mr. Greenleaf earned a Master of Business Administration from St. Joseph’s University, Philadelphia,

and Bachelor of Science from Western Connecticut State University, Danbury, Conn.

“Altimmune’s exceptional recent progress has positioned

it for a successful transition into a late-stage development company," said Mr. Greenleaf. “I look forward to working

with the Board and management team in our efforts to establish Altimmune as a potential category leader in the treatment of liver diseases

and fully realize the strategic value of pemvidutide.”

Mr. Howarth is an industry leading financial executive with a

lengthy record of success within commercial-stage public and private biotech and specialty pharma companies, including completing more

than 30 licensing and M&A transactions. He most recently served as Chief Financial Officer (CFO) with Madrigal Pharmaceuticals, leading

strategic planning to transition the company into a commercial organization that launched the first approved treatment for MASH. Prior

to joining Madrigal, Mr. Howarth was Chief Operating Officer of Akcea Therapeutics, where he led its sale in a transaction valued

at $2 billion. Earlier roles include President and CFO at Lycera Corporation and CFO at moksha8. Mr. Howarth is a Fellow Chartered

Accountant and holds a BSc in Biochemistry from the University of Bath in the United Kingdom.

"Altimmune’s strategic plan and balance sheet are strong,

offering significant leverage to support future growth," said Mr. Howarth. “I am eager to work with my Board colleagues

to capitalize on these and other drivers to move pemvidutide quickly and efficiently through Phase 3 development and towards commercialization.”

About Pemvidutide

Pemvidutide is a novel, investigational peptide with balanced 1:1 glucagon/GLP-1

dual receptor agonist activity that has an effect on reducing liver fat, inflammation, and fibrosis, in development for the treatment

of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). The

activation of glucagon receptors results in direct effects on the liver, while GLP-1 receptors mediate metabolic effects such as appetite

suppression and weight loss and are involved in pathways related to craving and reward.

The FDA granted Fast Track designations to pemvidutide for the treatment

of MASH and AUD, as well as Breakthrough Therapy Designation for MASH. In December 2025, the Company announced topline 48-week data

from the IMPACT Phase 2b trial in MASH. In July 2026, the PERFORMA Phase 3 trial, a global, randomized, double-blind, placebo-controlled,

parallel-group study of pemvidutide in patients with MASH was initiated. In July 2026, the Company announced positive topline results

from the RECLAIM Phase 2 trial in AUD. In August 2026, the Company announced completion of enrollment of the RESTORE Phase 2 trial

in ALD.

About Altimmune

Altimmune is a late clinical-stage biopharmaceutical company developing

pemvidutide for patients with serious liver diseases. Pemvidutide, a unique dual-action investigational therapy targeting both glucagon

and GLP-1 receptors in a balanced 1:1 ratio, is in late-stage clinical development for the treatment of metabolic dysfunction-associated

steatohepatitis (MASH), recently showed robust results in the RECLAIM Phase 2 trial in alcohol use disorder (AUD) and is being studied

in alcohol-associated liver disease (ALD). For more information, please visit www.altimmune.com

As of November 1, 2026, Altimmune’s new address is 350 Mount

Kemble Avenue, Suite 1001, Morristown, NJ 07960.

Follow @Altimmune, Inc. on LinkedIn

Follow @AltimmuneInc on X

Forward-Looking Statements

Any statements made in this press release related to the Company’s

board succession planning, development or commercialization of pemvidutide, an investigational product candidate, and other business,

regulatory and financial matters including without limitation, clinical trial study design, status, correspondence, results and data,

including the ongoing PERFORMA and RESTORE trials, the timing of key milestones for the Company’s clinical programs, future plans

or expectations for pemvidutide for the treatment of MASH, AUD and ALD, the potential benefits of Fast Track and Breakthrough Therapy

Designations, including potential regulatory timeline and approval benefits, the Company’s financial position, and the prospects

for receiving regulatory approval or commercializing or selling any product or drug candidates are forward-looking statements within

the meaning of the Private Securities Litigation Reform Act of 1995. In addition, when or if used in this press release, the words "may,"

"could," "should," "anticipate," "believe," "estimate," "expect," "intend,"

"plan," "predict" and similar expressions and their variants, as they relate to Altimmune, Inc. may

identify forward-looking statements. The Company cautions that these forward-looking statements are subject to numerous assumptions,

risks, and uncertainties, which change over time. Important factors that may cause actual results to differ materially from the results

discussed in the forward-looking statements or historical experience include risks and uncertainties, including risks relating to: delays

in regulatory review, manufacturing and supply chain interruptions, access to clinical sites, enrollment, adverse effects on healthcare

systems and disruption of the global economy; the reliability of the results of studies relating to human safety and possible adverse

effects resulting from the administration of the Company's product candidates; the Company's ability to manufacture clinical trial materials

on the timelines anticipated; and the success of future product advancements, including the success of future clinical trials. Further

information on the factors and risks that could affect the Company's business, financial conditions and results of operations are contained

in the Company's filings with the U.S. Securities and Exchange Commission, including under the heading "Risk Factors" in the

Company's most recent annual report on Form 10-K, quarterly report on Form 10-Q and the Company’s other filings with

the SEC, which are available at www.sec.gov.

Investor Contact:

Luis Sanay, CFA

ir@altimmune.com

Media Contact:

Marisa Sharkey

media@altimmune.com

GRAPHIC

Filename: tm2628339d1_ex99-1img001.jpg · Sequence: 6

Binary file (2790 bytes)

Download tm2628339d1_ex99-1img001.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.3

Cover

Oct. 23, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Oct. 23, 2026

Entity File Number

001-32587

Entity Registrant Name

ALTIMMUNE, Inc.

Entity Central Index Key

0001326190

Entity Tax Identification Number

20-2726770

Entity Incorporation, State or Country Code

Entity Address, Address Line One

910 Clopper Road,

Entity Address, Address Line Two

Suite 201S

Entity Address, City or Town

Gaithersburg

Entity Address, State or Province

Entity Address, Postal Zip Code

20878

City Area Code

240

Local Phone Number

654-1450

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common stock, par value $0.0001 per share

Trading Symbol

ALT

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration